A Study of Clinical Outcomes Associated with Lenvatinib Treatment in Patients with Anaplastic Thyroid Cancer

Overview

About this study

The purpose of this study is to assess the use of lenvatinib to treat anaplastic thyroid cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients ≥ 18 years of age
  • Anaplastic Thyroid Cancer (ATC)
  • Receiving lenvatinib

Exclusion Criteria:

  • Patients less than 18 years of age
  • Patients without ATC and/or
  • Patients with ATC not receiving lenvatinib

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mabel Ryder, M.D.

Closed for enrollment

Contact information:

Mabel Ryder M.D.

(507)293-0552

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions